Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Online diet program shows promise for fatty liver

NCT ID NCT06503120

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a 12-week online Mediterranean diet program could reduce liver fat in people with a type of fatty liver disease (MASLD). 78 adults followed either the diet program or received standard advice. The goal was to see if the diet could improve liver health and related measures like blood sugar and cholesterol.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

78 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing to change diet for at least three months (accepting reduced sugar, less processed foods, reduced red meat, and following a Mediterranean diet with olive oil, high-fiber foods, vegetables, fruits, nuts, and legumes) * Intrahepatic triglyceride content (IHTG) of 5% * Age 18 to 70 years * Fulfill the diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease * Baseline Mediterranean Diet Adherence Screener (T-MEDAS) score equal to or less than 5 * Participants must not have initiated any new probiotic treatment in the past three months or must have been on a stable probiotic regimen for at least three months, which they are willing to continue for the duration of the study Exclusion Criteria: * Other liver disease (viral hepatitis, autoimmune or cholestatic liver disease, Wilson's disease, hemochromatosis, or alpha-1 anti-trypsin deficiency) * Unstable body weight (variation \>5% within the preceding 3-month period) * Current use of weight loss medications (e.g., Liraglutide) * Current use of pioglitazone * Unstable diabetes (HbA1c \>8.5%) * Decompensated cirrhosis (international normalized ratio \>1.3, platelets \<100 × 109/mm, bilirubin \>20 mmol/L, albumin \<35 g/L, ascites, or hepatic encephalopathy) * A serum creatinine level ≥ 2mg/dL * Presence of active cancer or undergoing chemotherapy either at present or in the prior three years * Major illness that might require hospitalization * Pregnancy or lactation for women * Participation in another trial * Chronic treatment with warfarin (given its interaction with vitamin K) * Being implanted with a pacemaker or platinum implant (due to inability to undergo magnetic resonance imaging included in the study design) * Alcohol consumption above 30 g per day in men or 20 g per day in women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diet, healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Taichung Veterans General Hospital

    Taichung, Taichung, 407219, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.